Beneficial effects of CHF6467, a modified human nerve growth factor, in experimental neonatal hypoxic–ischaemic encephalopathy
British Journal of Pharmacology · 2025-02 · 182 (3) · 510-529
DOI: 10.1111/bph.17353 ↗At a glance
Journal article in British Journal of Pharmacology, 2025-02. Written by Elisa Landucci and 11 co-authors. Institution: Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy. Major MEDLINE topics: Hypoxia-Ischemia, Brain, Animals, Newborn, Nerve Growth Factor, Neuroprotective Agents. Cited 6 times so far (Crossref); 51 references. Funded by: Chiesi Farmaceutici, Parma, Italy.
Abstract (original language)
Background and Purpose Therapeutic hypothermia (TH) has become the standard care to reduce morbidity and mortality in neonates affected by moderate‐to‐severe hypoxic–ischaemic encephalopathy (HIE). Despite the use of TH for HIE, the incidence of mortality and disabilities remains high. Experimental Approach Nerve growth factor (NGF) is a potent neurotrophin, but clinical use is limited by its pain eliciting effects. CHF6467 is a recombinant modified form of human NGF devoid of algogenic activity (painless NGF). Key Results In rodent hippocampal slices exposed to oxygen and glucose deprivation, CHF6467 protected neurons from death and reverted neurotransmission impairment when combined with hypothermia. In a model of rat neonatal HIE, intranasal CHF6467 (20 μg kg −1 ) significantly reduced brain infarct volume versus vehicle when delivered 10 min or 3 h after the insult. CHF6467 (20 and 40 μg kg −1 , i.n.), significantly decreased brain infarct volume to a similar extent to TH and when combined, showed a synergistic neuroprotective effect. CHF6467 (20 μg kg −1 , i.n.) per se and in combination with hypothermia reversed locomotor coordination impairment (Rotarod test) and memory deficits (Y‐maze and novel object recognition test) in the neonatal HIE rat model. Intranasal administration of CHF6467 resulted in meaningful concentrations in the brain, blunted HIE‐induced mRNA elevation of brain neuroinflammatory markers and, when combined to TH, significantly counteracted the increase in plasma levels of neurofilament light chain, a peripheral marker of neuroaxonal damage. Conclusion and Implications CHF6467 administered intranasally is a promising therapy, in combination with TH, for the treatment of HIE.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
- Laboratory Pharmacology of Synaptic Plasticity, European Brain Research Institute, Rome, Italy.
- School of Pharmacy, University of Rome "Tor Vergata", Rome, Italy.
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
- Corporate Preclinical R&D, Chiesi Farmaceutici, Parma, Italy.
ORCID profiles: Fabrizio Facchinetti
Funding
- Chiesi Farmaceutici, Parma, Italy
Cite
APA
Landucci, E., Mango, D., Carloni, S., Mazzantini, C., Pellegrini-Giampietro, D. E., Saidi, A., Balduini, W., Schiavi, E., Tigli, L., Pioselli, B., Imbimbo, B. P., & Facchinetti, F. (2025). Beneficial effects of CHF6467, a modified human nerve growth factor, in experimental neonatal hypoxic–ischaemic encephalopathy. British Journal of Pharmacology. https://doi.org/10.1111/bph.17353
Vancouver
Landucci E, Mango D, Carloni S, Mazzantini C, Pellegrini-Giampietro DE, Saidi A, et al. Beneficial effects of CHF6467, a modified human nerve growth factor, in experimental neonatal hypoxic–ischaemic encephalopathy. British Journal of Pharmacology. 2025. doi:10.1111/bph.17353
BibTeX
@article{Landucci2025,
author = {Landucci, Elisa and Mango, Dalila and Carloni, Silvia and Mazzantini, Costanza and Pellegrini-Giampietro, Domenico E and Saidi, Amira and Balduini, Walter and Schiavi, Elisa and Tigli, Laura and Pioselli, Barbara and Imbimbo, Bruno P and Facchinetti, Fabrizio},
title = {Beneficial effects of CHF6467, a modified human nerve growth factor, in experimental neonatal hypoxic–ischaemic encephalopathy},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17353}
}
EUVIMED